The fold-change analysis obtained from the Gene Globe software revealed upregulation of IL-6 (p < 0.005), Fas (p < 0.005), NOS2 (p < 0.005), VEGF-A (p < 0.005), NR4A3 (p < 0.001), MKi67 (p < 0.005), and EpCAM (p < 0.005) in Group 3 patients when compared with non-CCA subjects. This evidence concerns the gene EPCAM and cholangiocarcinoma.